Condition: Essential Thrombocythemia (ET) · Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) · Myeloproliferative Neoplasms (MPN) · Sponsor: Jubilant Therapeutics Inc.
This study aims to assess the safety and efficacy of orally administered JBI-802 in subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis. Who is it for? You may be eligible to join this study if you are aged 18 years and over have been diagnosed with Essential Thrombocythemia and either a Morphologically confirmed diagnosis of Myeloproliferative Neoplasms (MPN) or Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). Study details: Participants in this study will receive JBI-802 administered orally daily for a 28 day treatment cycle for up to 2-years as long as the participant experiences clinical benefit in the opinion of the Investigator and shows no signs or symptoms of unequivocal progression of disease, unacceptable toxicity, or other reasons for study discontinuation. The starting dose of the study drug is 5 mg/day, a total dose of 35 mg. Dose escalation will occur as per the 3+3 design after an internal Safety Review Committee (SRC) review of each dose stage. Dose expansion to other subtypes of MPN and MDS/MPN will occur after Recommended Phase 2 Dose is determined from the dose escalation phase. Eligibility/Screening for this study will occur within 21 days prior to starting treatment. If the study is suitable for you, you will enter the treatment period. The dose level selected for evaluation in Phase 2 will only be selected if it was safe and well tolerated during Phase 1. The treatment…
This description comes directly from the study's public registry record.
Melda Dolan · +1 267 888 4319 · melda.dolan@jubl.com
Always discuss trial participation with your own doctor first.
| St. Vincent's Hospital Sydney Limited | Sydney, New South Wales, Australia | Recruiting |
| Macquarie University | Sydney, New South Wales, Australia | Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| St Vincent's Hospital (Melbourne) | Melbourne, Victoria, Australia | Recruiting |
| Monash Medical Centre | Melbourne, Victoria, Australia | Recruiting |
| The Perth Blood Institute Limited | Perth, Western Australia, Australia | Recruiting |
| Hollywood Private Hospital | Nedlands, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07612280